HRT and Ovarian Cancer Risk: The Real Numbers, and the Finding That Changes the Conversation
Put the ovarian-cancer evidence in context
Find My HRT Path helps organize the care route by symptoms, surgical history, safety history, budget, and state. It cannot evaluate ovarian-cancer symptoms, interpret BRCA results, or replace oncology, genetics, or gynecology care.
HRT and ovarian cancer risk is real and small: the largest individual-participant analysis estimated about one additional case per 1,000 women using systemic hormone therapy for five years from around age 50, if the association is causal. This page is for women deciding about HRT — not anyone with current symptoms, a known high-risk gene, or prior ovarian cancer.
Here is the part almost nobody tells you.
For years, the standard line was that estrogen-only and estrogen-plus-progestogen hormone therapy carried roughly similar ovarian cancer risk. The 2024 long-term Women's Health Initiative follow-up found something more complicated. In one randomized trial, oral conjugated equine estrogen taken alone after hysterectomy significantly increased ovarian cancer cases and deaths. In the separate trial of oral conjugated equine estrogen plus medroxyprogesterone acetate, the increase was not statistically significant.
Those were two different trials in two different populations, not a head-to-head test of every estrogen-only product against every combined product. They do not prove that every estrogen-only prescription raises risk or that every combined prescription does not.
But they are different results.
Two women, two prescriptions, two different answers.
And when we read all six FDA labels updated in February 2026 line by line, we found that every one still uses the older observational evidence in its ovarian cancer warning. None cites the 2024 long-term WHI paper.
That does not make the labels wrong. It means the single class-wide number on a label cannot answer the treatment-specific question on its own.
That's what this page is about. Not just “is there a link?” — yes, there is a link, and we'll show you exactly how big. This page is about which evidence applies to your prescription, what it cannot tell you, and what to do next.
The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.
Who is this page for — and who needs a different starting point?
This page is for you if you still have at least one ovary, you have not been diagnosed with ovarian cancer, and the cancer question is the thing standing between you and a decision about menopausal hormone therapy.
This page is not enough on its own if any of these describe you:
- You have new bloating, pelvic or abdominal pain, feeling full quickly, or urinary urgency or frequency that has become persistent or is a change from your normal. That pattern needs evaluation, not another risk statistic. Jump to the symptom section →
- You have any bleeding after menopause. Get that evaluated promptly, whether or not you use HRT.
- You know you carry a BRCA1, BRCA2, or Lynch syndrome pathogenic variant. Your baseline risk is different enough that a general page cannot serve you well. Jump to the family-history section →
- You have had ovarian, fallopian tube, or primary peritoneal cancer. That is an oncology-led decision. Jump to the survivor section →
What does the evidence mean for your situation?
The same headline does not fit every woman. Your uterus, ovaries, exact hormone regimen, route, family history, inherited-risk status, and current symptoms determine which evidence is relevant. Find your row first; the rest of the page explains the numbers without pretending that a population average is your personal risk.
| Your situation | What the evidence supports | What it cannot decide | Your next step |
|---|---|---|---|
| You have a uterus and are considering estrogen plus a progestogen | In the WHI trial of oral conjugated equine estrogen plus medroxyprogesterone acetate, ovarian cancer incidence was not significantly increased after long-term follow-up. Observational studies still report a small association for combined therapy overall | Whether micronized progesterone, a different progestogen, a patch, a gel, or another dose has the same ovarian-cancer profile | A normal HRT consult. Ask which exact estrogen and progestogen are being proposed and why |
| You have had a hysterectomy and are considering estrogen alone | This is where the randomized signal appeared: oral conjugated equine estrogen alone increased ovarian cancer incidence and mortality in the WHI follow-up | Whether a modern estradiol patch, gel, spray, or lower dose behaves the same way. The trial did not test those products | Bring the exact WHI finding to your prescriber. Do not stop or change prescribed HRT from an article |
| You are considering low-dose vaginal estrogen for dryness or painful sex | Systemic HRT risk estimates should not be applied automatically. The Estring label says systemic exposure is generally lower and the relevance of systemic risks is unknown | That the ovarian-cancer risk is zero, or that every vaginal product has the same exposure | Confirm that your product is a low-dose local treatment, not a systemic-dose vaginal ring |
| Ovarian cancer runs in your family | Family history can raise baseline risk. The 2015 analysis did not find that family history materially changed the proportional HRT association | Whether you carry an inherited cancer-predisposition variant | Use a brief familial-risk assessment and pursue genetic counseling or testing when indicated |
| You know you carry BRCA1, BRCA2, or Lynch syndrome | NCI estimates lifetime ovarian-cancer risk at 39%–58% for BRCA1 and 13%–29% for BRCA2, compared with about 1.1% in the general population | A general-population HRT article cannot translate that into a safe personal plan | A genetics or high-risk clinic, coordinated with menopause care — not a routine online intake |
| Both ovaries and fallopian tubes were removed | Ovarian and fallopian-tube cancer risk is greatly reduced, although primary peritoneal cancer can still occur, especially with inherited risk | Your wider benefits and risks of hormone therapy after surgical menopause | Make the decision around age, symptoms, surgical timing, bone and cardiovascular health, and cancer history |
| You have new persistent symptoms now | Symptoms need evaluation rather than a population-risk calculation | Whether HRT caused them or whether cancer is present | Arrange an in-person assessment, then return to the HRT decision |
Find your row. The rest of this page explains it.
The handoff we owe you before you go further
The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.
→ See which HRT care path fits your history — about 90 seconds, no email required, and your health answers stay in your browser.
What did we actually verify for this page?
On August 6, 2026, we read all six prescribing-information documents in the FDA's first February 2026 menopausal-hormone-therapy relabeling batch. We checked each boxed warning, contraindications, ovarian-cancer warning, pharmacology where relevant, references, revision date, and whether the 2024 long-term WHI ovarian-cancer paper appeared in the reference list.
| FDA label read in full | FDA Reference ID | Revision | What we verified in the ovarian-cancer section |
|---|---|---|---|
| Divigel — estradiol gel | 5744952 | 2/2026 | Uses an observational estrogen-only estimate of RR 1.37; duration associated with increased risk is described as unknown |
| Cenestin — synthetic conjugated estrogens | 5744928 | 2/2026 | Uses the same class-level observational estimate for current estrogen-only use |
| Enjuvia — synthetic conjugated estrogens | 5744927 | 2/2026 | Uses the same class-level observational estimate for current estrogen-only use |
| Estring — low-dose estradiol vaginal ring | 5744942 | 2/2026 | Prints the class estimate while stating that systemic exposure is generally lower and the relevance or extent of systemic risks is unknown |
| Bijuva — estradiol plus progesterone | 5744948 | 2/2026 | Includes WHI conjugated-estrogen-plus-medroxyprogesterone figures and the observational meta-analysis; wide confidence intervals cross 1 |
| Prometrium — progesterone | 5744934 | 2/2026 | Includes ovarian-cancer evidence from combined estrogen-plus-progestin use because the capsule is used with estrogen in women with a uterus |
All six labels were revised in February 2026. All six include ovarian-cancer warning language. None of the six reference lists cites the 2024 WHI long-term ovarian and endometrial cancer analysis.
What this verification does not prove: it does not prove that the FDA rejected, overlooked, or disagreed with the 2024 paper. Drug labels are product-specific regulatory documents, and label changes occur application by application. Our narrower finding is exactly what we could reproduce: the paper is not cited in these six February 2026 labels.
We are not clinicians, this page has not been reviewed by one, and nothing here is a personal risk assessment.
Does HRT cause ovarian cancer, or is it only associated with it?
Large observational studies consistently find more ovarian cancers among current or recent menopausal hormone therapy users than among never-users. The authors of the largest individual-participant meta-analysis wrote that the increase “may well be largely or wholly causal.” That is stronger than “just correlation,” but it is not the same as randomized proof for every regimen.
Here's the honest version of a distinction that gets flattened everywhere else.
When researchers compare women who took HRT with women who did not, they are not comparing identical people. HRT users may differ in healthcare use, reproductive history, body size, oral-contraceptive use, smoking, and other factors that can affect ovarian-cancer risk. Researchers adjust for what they measured. They cannot adjust perfectly for what they did not measure.
That is why the language in the 2015 Lancet analysis matters. Not “HRT definitely causes ovarian cancer.” Not “it is meaningless correlation.” The investigators examined the pattern across 52 studies and concluded that the association may be causal, while disclosing a serious limitation: about half of the studies with relevant information had not been published.
We're telling you that because it cuts against the clean headline number on this page. It is still the most widely cited absolute-risk estimate.
Randomized evidence gets closer to causation, but it has its own limits here. The WHI randomized two different populations into two separate trials of two exact oral regimens. One produced a significant long-term signal; the other did not. That is stronger evidence about those regimens than an observational association — but it is not a universal answer for estradiol patches, gels, sprays, different progestogens, compounded preparations, or low-dose vaginal estrogen.
One thing this means practically: a diagnosis after starting HRT does not prove that HRT caused that cancer. Sequence is not enough. The population evidence can inform a decision; it cannot reconstruct the cause of one woman's tumor.
How big is HRT and ovarian cancer risk in real numbers?
The most cited estimate is about one additional ovarian cancer per 1,000 women who use systemic menopausal hormone therapy for five years from around age 50, and about one additional ovarian-cancer death per 1,700 users — if the observed association is causal. The estimate came from 52 epidemiological studies including 21,488 women with ovarian cancer.
Let's make that concrete, because “relative risk 1.37” is the number that scares people and it shouldn't be allowed to float without a denominator.
Picture 1,000 women around age 50 using systemic HRT for five years. The 2015 analysis estimated that, if the association is causal, the group would have about one more ovarian-cancer diagnosis than a comparable group that did not use HRT.
That does not identify which woman will develop cancer. It does not mean one specific woman has a 1-in-1,000 total risk. It is an estimated difference between groups over a defined use period.
Relative risk 1.37 means the observed rate among current users was about 37% higher than among never-users. It does not mean a woman has a 37% chance of ovarian cancer. When an outcome is uncommon, a noticeable relative increase can still translate into a small absolute difference.
What baseline do those numbers sit on?
The five-year HRT estimate and the lifetime ovarian-cancer estimate measure different periods, so they should sit beside each other — not be multiplied together. For 2026, the American Cancer Society estimates 21,010 US diagnoses and 12,450 deaths; lifetime risk is about 1 in 91 for diagnosis and 1 in 143 for death.
- 21,010 new ovarian-cancer diagnoses expected in the United States in 2026
- 12,450 deaths expected in 2026
- Lifetime risk of developing ovarian cancer: about 1 in 91
- Lifetime risk of dying from ovarian cancer: about 1 in 143
- About half of women diagnosed are 63 or older
The American Cancer Society also says incidence has fallen over several decades, likely in part because of increased oral-contraceptive use and reduced menopausal hormone therapy use. That is a population-level observation, not a personal risk calculator.
Please don't do this math
Do not take the roughly 1.1% lifetime risk and multiply it by 1.37 to calculate “your risk on HRT.” The lifetime figure spans all ages. The 1.37 estimate concerns current or recent users over defined observation windows. Multiplying them mixes different time horizons and populations and creates a number the studies did not report.
Why do different studies give different answers?
The studies are answering different questions: real-world associations versus randomized effects, current use versus decades of follow-up, specific oral regimens versus pooled products, and all ovarian cancers versus individual subtypes. The table below is the evidence conflict in one place — not a contest with one automatic winner.
| Evidence source | Main result | What was studied | What the result can support |
|---|---|---|---|
| Collaborative Group, Lancet 2015 | Current/recent use RR 1.37; about 1 additional case per 1,000 over 5 years, if causal | Individual-participant meta-analysis of 52 observational studies; 21,488 cases | Best-known population estimate, but not proof of causation or a product-specific effect |
| WHI long-term follow-up 2024 — CEE alone | Incidence HR 2.04; mortality HR 2.79 | Randomized oral conjugated equine estrogen 0.625 mg in women with prior hysterectomy | A long-term signal for this exact estrogen-only regimen and population |
| WHI long-term follow-up 2024 — CEE plus MPA | Incidence HR 1.14 (95% CI 0.82–1.59); not statistically significant | Randomized oral CEE 0.625 mg plus medroxyprogesterone acetate 2.5 mg in women with a uterus | No significant increase detected for this exact combined regimen; not proof that all combined HRT is neutral |
| Systematic review and meta-analysis, 2024 | Cohort RR 1.20; case-control OR 1.13 | 21 cohort studies covering about 4.56 million women plus 30 case-control studies | A smaller pooled association than the 2015 estimate; still observational |
| French E3N cohort, 2023 | No significant estrogen-only association; higher risk with current/recent estrogen plus progesterone or dydrogesterone | More than 75,000 postmenopausal women; treatment types analyzed separately | Evidence that results can vary by regimen and progestogen; it conflicts with a simple “estrogen alone bad, combined good” rule |
| Subtype meta-analysis, 2019 | Serous RR 1.50; endometrioid RR 1.48 | Pooled observational studies by ovarian-cancer subtype | The observed association is not evenly distributed across tumor types |
Notice what that table does. It does not crown a winner. It shows why “how much does HRT raise ovarian cancer risk?” has more than one defensible answer until you say which regimen, which route, which population, and which study design.
The next section is the one that sorts out the result that changed the conversation.
Does estrogen-only HRT carry a different ovarian cancer risk from combined HRT?
The 2024 WHI follow-up found a significant long-term ovarian-cancer increase with oral conjugated equine estrogen alone, while the separate trial of oral conjugated equine estrogen plus medroxyprogesterone acetate did not show a significant increase. That difference matters — but it applies to two exact oral regimens in two different trial populations, not every estrogen-only and combined prescription.
This is the most important correction on the page.
The WHI evidence is randomized and long-term. That gives it unusual weight. But the two arms were separate trials, not a direct randomized comparison between estrogen alone and estrogen plus a progestogen. Women entered one trial or the other based on whether they had a uterus.
What did the estrogen-alone trial find?
The estrogen-alone trial followed 10,739 postmenopausal women with prior hysterectomy who were randomized to oral conjugated equine estrogen 0.625 mg or placebo. After long-term follow-up, ovarian-cancer incidence was 35 versus 17 cases, and ovarian-cancer mortality was 25 versus 9 deaths. The confidence intervals excluded 1.
| Outcome | Oral CEE alone | Placebo | Effect estimate |
|---|---|---|---|
| Ovarian cancer cases | 35 | 17 | HR 2.04 (95% CI 1.14–3.65) |
| Ovarian cancer deaths | 25 | 9 | HR 2.79 (95% CI 1.30–5.99) |
| Annualized incidence | 0.041% | 0.020% | — |
| Annualized ovarian-cancer mortality | 0.024% | 0.008% | — |
Two details matter enormously.
First: statistical separation emerged late. The investigators reported that the increased incidence became statistically significant after about 12 years of follow-up. That does not prove the biological effect began in year 12. It means the difference was not statistically established earlier.
Second: look at the absolute numbers. Thirty-five cancers versus seventeen across 10,739 women over long-term follow-up. The relative effect is large. The absolute number of events is small. Both things are true at once.
The trial tested one older oral product at one dose: conjugated equine estrogen 0.625 mg. It did not test transdermal estradiol, estradiol gel, lower-dose oral estradiol, or compounded estrogen.
What did the combined-therapy trial find?
The combined trial followed 16,608 women with a uterus who were randomized to oral conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg or placebo. Ovarian cancer occurred in 75 versus 63 women: HR 1.14, with a 95% confidence interval of 0.82–1.59. That is not a statistically significant increase.
The same trial found fewer endometrial cancers with the combined regimen: 106 versus 140, HR 0.72.
“No statistically significant increase” is the accurate sentence. “Combined HRT did not raise ovarian cancer at all” is not.
The point estimate was above 1, and the confidence interval includes both a possible decrease and a possible increase. The trial did not prove zero effect. It also did not test estradiol plus micronized progesterone, estradiol plus dydrogesterone, an intrauterine progestogen, or every modern route and dose.
Why can't we turn this into a simple regimen rule?
Other evidence does not line up neatly behind one rule. The 2015 observational analysis reported similar associations for estrogen-only and estrogen-plus-progestogen therapy. The 2023 French E3N cohort found no significant estrogen-only association but a higher risk with current or recent estrogen plus progesterone or dydrogesterone. Regimen details matter, and the evidence conflicts.
That conflict is not a reason to throw out the WHI result. It is a reason to stop expanding it beyond what was tested.
What must you not conclude from this?
We're going to be firm here, because this is where health writing goes wrong.
Do not read this as “combined HRT is safe for your ovaries.” The WHI did not find a significant increase with one exact CEE-plus-MPA regimen. That is not proof of no ovarian-cancer effect for every combined product. Combined therapy also has other trade-offs that belong in the full HRT decision, including breast-cancer evidence that cannot be reduced to this page.
Do not read this as “estrogen-only HRT is dangerous.” The WHI signal came from oral conjugated equine estrogen, at one dose, in women with prior hysterectomy. The absolute event count remained small, and no comparable long-term randomized trial has tested a modern estradiol patch or gel for ovarian-cancer outcomes.
Do not add progesterone to estrogen solely because of this article. A progestogen is normally used to protect the endometrium when a uterus is present. Adding one after hysterectomy can introduce other risks and side effects. That decision belongs with a prescriber who can weigh the entire benefit-risk picture.
If you've had a hysterectomy and use or are considering estrogen alone, you are the reader this section is for. This is not a reason to stop treatment. It is a reason to bring one precise question to the person prescribing it:
“The long-term WHI follow-up found an ovarian-cancer signal with oral conjugated equine estrogen alone. Does that evidence change anything about my exact product, route, dose, or review plan?”
→ See which HRT care path fits your history — the tool asks whether you have a uterus, which is the exact fork this section turns on.
What did the FDA's February 2026 HRT label change actually do?
On February 12, 2026, the FDA announced approved label changes for six menopausal hormone therapy products. The changes removed specified boxed-warning statements about cardiovascular disease, breast cancer, and probable dementia. Ovarian cancer was never a boxed-warning item; it remains in the Warnings or Warnings and Precautions sections of all six labels we audited.
If you saw a headline saying the FDA “removed the cancer warning from HRT,” this is the correction.
The FDA began the broader process in November 2025. Twenty-nine companies submitted proposed label changes, and six products were included in the first approved batch. We read all six.
What do the six updated labels say about ovarian cancer?
The six February 2026 labels do not use one identical paragraph, but they all retain ovarian-cancer warning language. Estrogen-only and Estring labels use an observational RR of 1.37 for current use. Bijuva and Prometrium also present older WHI combined-regimen figures. None cites the 2024 long-term WHI ovarian-cancer analysis.
| Product | Treatment category | Boxed warning after the 2026 change | Ovarian-cancer evidence carried in the label |
|---|---|---|---|
| Divigel | Systemic estradiol gel, estrogen alone | Endometrial cancer | Observational estrogen-only current-use RR 1.37; duration associated with increased risk unknown |
| Cenestin | Systemic synthetic conjugated estrogens | Endometrial cancer | Same class-level observational estrogen-only estimate |
| Enjuvia | Systemic synthetic conjugated estrogens | Endometrial cancer | Same class-level observational estrogen-only estimate |
| Estring | Low-dose vaginal estradiol ring | No boxed warning | Same class estimate, preceded by language that systemic exposure is generally lower and relevance of systemic risks is unknown |
| Bijuva | Systemic estradiol plus progesterone | No boxed warning | WHI CEE-plus-MPA figures plus the observational meta-analysis; confidence intervals for the WHI ovarian results cross 1 |
| Prometrium | Progesterone capsule used with estrogen when indicated | No boxed warning | Combined-therapy ovarian evidence, including WHI CEE-plus-MPA figures and the observational meta-analysis |
The FDA's current product list links the six revised prescribing-information documents.
The finding inside the finding
Every one of the six labels includes older ovarian-cancer evidence. None of the six reference lists includes the 2024 long-term WHI analysis.
So a prescriber reading a February 2026 label can see the class-wide observational estimate without seeing the newer long-term randomized split between the exact CEE-alone and CEE-plus-MPA regimens.
Again: the labels are not “false.” The 2015 analysis was enormous and remains relevant. The original verification is narrower and more useful than that accusation:
The six February 2026 labels we audited do not cite the 2024 long-term WHI ovarian-cancer paper.
That is why a label needs context rather than blind dismissal or blind repetition.
Is ovarian cancer a contraindication to starting HRT?
In the six labels audited, ovarian cancer and family history of ovarian cancer are not named as contraindications. They appear in warning or risk discussions rather than the “do not use” list. That does not make HRT appropriate for every woman, especially after ovarian cancer; contraindications and specialist decisions still depend on the product and medical history.
A contraindication is the product's Section 4 “do not use” list. A warning describes a risk that must be considered.
The exact contraindication lists differ by product. Common items across systemic estrogen-containing products include undiagnosed abnormal genital bleeding, certain estrogen-dependent cancers, active or prior thromboembolic or arterial events, liver impairment or disease, and hypersensitivity. Do not substitute a summary table on this site for the label attached to your own product.
Family history of ovarian cancer is not, by itself, printed as a contraindication in the six labels.
How should you read an ovarian-cancer warning on your own label?
A label tells you which evidence the FDA and manufacturer included for that product; it does not turn a pooled class estimate into a precise personal probability. Read the product name, route, revision date, warning source, and the exact regimen studied before treating one relative-risk number as if it belongs equally to every estrogen formulation.
| What the label says | What it does not prove |
|---|---|
| Current use was associated with a relative risk around 1.37 in the cited observational research | That every estrogen product, dose, route, and duration carries exactly the same risk |
| The CEE-plus-MPA trial did not show a significant ovarian-cancer increase | That every combined HRT regimen has no effect |
| The duration associated with increased risk is unknown in several labels | That every duration carries equal risk or that a five-year cutoff is “safe” |
| Estring produces lower systemic exposure | That its ovarian-cancer risk is zero |
| The WHI trials tested specific oral regimens | That a patch or gel is automatically safer for ovarian cancer |
Look at the revision date on the final pages of your leaflet or prescribing information. Products and manufacturers are moving through relabeling on different timelines, so two leaflets may not use the same wording even when the medications seem similar.
Which ovarian cancer subtypes are linked to HRT?
Ovarian cancer is not one disease. In the 2015 individual-participant analysis, the definite increase appeared in serous and endometrioid cancers, not mucinous or clear-cell cancers. A 2019 meta-analysis estimated relative risks of 1.50 for serous and 1.48 for endometrioid disease. These are observational subtype results, not proof of mechanism.
| Subtype | What pooled observational evidence found |
|---|---|
| Serous | Increased association; 2019 pooled estimate RR 1.50 (95% CI 1.35–1.68) |
| Endometrioid | Increased association; 2019 pooled estimate RR 1.48 (95% CI 1.13–1.94) |
| Mucinous | No significant increase found in the pooled analysis |
| Clear cell | No significant increase found in the pooled analysis |
This matters more than it sounds like it should.
A subtype pattern can support biological plausibility because the association is not distributed evenly across every tumor category. But it does not, by itself, prove that hormone therapy caused the cancers. Subtype classification, exposure measurement, and confounding can still affect observational results.
It also explains why two studies can look inconsistent when one combines all ovarian cancers and another separates histologies.
Does a pill, patch, or gel change ovarian cancer risk?
No good evidence shows that a transdermal patch or gel removes ovarian-cancer risk. The randomized signal came from oral conjugated equine estrogen, while observational studies often pooled products or lacked enough route-specific cases. A patch may be chosen for other clinical reasons, but “ovarian-safe” is a claim the evidence does not support.
This one frustrates people, so let's be precise about what is known and what is not.
- The WHI trial that found the estrogen-alone signal used oral conjugated equine estrogen 0.625 mg.
- The trial did not test transdermal estradiol patches, estradiol gel, estradiol spray, or lower-dose oral estradiol.
- A NICE evidence review found insufficient route-specific evidence to make a reliable ovarian-cancer distinction; the oral-versus-transdermal subgroup difference was not statistically significant.
- Divigel's FDA label carries the same class-level observational estimate used in oral estrogen labels because the source evidence does not establish a separate transdermal ovarian-cancer risk.
- FDA labels repeatedly warn that trial results from one dose, route, or product may not generalize to another.
If a provider tells you a patch eliminates ovarian cancer risk, that statement goes beyond the evidence. A patch can still be a reasonable choice for reasons that belong elsewhere in your HRT risk discussion. Ovarian-cancer proof is not one of them.
Does low-dose vaginal estrogen carry the same ovarian cancer risk?
Systemic risk estimates should not be applied automatically to low-dose vaginal estrogen. Estring releases about 7.5 micrograms of estradiol per day and produces low average serum estradiol levels, while its FDA label states that the relevance of systemic-estrogen risks is unknown. That is reassuring separation from systemic therapy — not proof of zero ovarian-cancer risk.
This is the clearest example on the page of a class warning traveling further than its direct evidence.
The February 2026 Estring label reports:
- Release of approximately 7.5 micrograms of estradiol per day
- Average serum estradiol concentrations of 7.8, 7.0, 7.0, and 8.1 pg/mL at weeks 12, 24, 36, and 48
- About 8% of the daily released amount absorbed systemically as unchanged estradiol, with a 95% confidence interval of 2.8%–12.8%
The same label says systemic absorption occurs, while systemic exposure is generally lower than with systemic estrogen therapy and the relevance or extent of systemic risks is not known.
The 2022 Menopause Society position statement recommends low-dose vaginal estrogen or other local therapies for bothersome genitourinary syndrome of menopause when over-the-counter options are not enough and systemic therapy is not otherwise indicated. It also notes minimal systemic absorption with low-dose vaginal products, while long-term randomized endpoint data remain limited.
Practical translation: if vaginal dryness, burning, urinary symptoms related to GSM, or pain with sex is the main problem, low-dose vaginal estrogen is a different exposure category from systemic HRT. The ovarian-cancer figure printed on Estring's label comes from systemic-hormone evidence, not a trial that measured ovarian-cancer outcomes with Estring.
That is not proof that the risk is zero, and we won't tell you it is.
One trap to avoid: not everything inserted vaginally is low-dose local therapy. Some vaginal rings are designed to deliver systemic estrogen for hot flashes. Check the product name and indication. A pharmacist can tell you which category you have.
For the route distinction in more depth, see Vaginal estrogen: how it differs from systemic HRT.
Does ovarian cancer risk go away after stopping HRT?
The association is strongest during current or recent use and declines after stopping. The exact timeline is unsettled. The 2015 analysis found residual elevation roughly 10 years after stopping among longer-duration users, while The Menopause Society's 2022 statement summarizes the excess risk as dissipating within about five years. Neither supports an instant reset or a guaranteed safe-duration cutoff.
Three things the evidence supports:
- The link is strongest during current or recent use. In the 2015 analysis, “recent” meant use within the previous five years.
- Risk declines after stopping. It does not behave like a permanent fixed multiplier in the observational data.
- The exact time to baseline is uncertain. Different summaries and analyses use different definitions, populations, and duration groups.
The 2015 analysis reported that women who had used HRT for at least five years still had some excess serous or endometrioid risk around ten years after stopping. The 2022 Menopause Society statement says the excess ovarian-cancer risk dissipates within five years of stopping.
Those statements are not cleanly identical. The honest conclusion is that the decline is real and the precise tail is not settled.
One thing the evidence does not support is a simple “under five years is safe” rule. The 2015 analysis found an association among current users with less than five years of use, and several FDA labels state that the duration associated with increased ovarian-cancer risk is unknown.
What this argues for is treating HRT as a decision you revisit, not one you make once and forget. Periodic review asks: are the symptoms still affecting your life, is the current route and dose still the right fit, and has your health or family history changed?
Can you take HRT if ovarian cancer runs in your family?
Family history can raise your baseline ovarian-cancer risk, but the 2015 meta-analysis did not find that family history materially changed the proportional HRT association. That does not rule out inherited risk. The right move is a validated familial-risk assessment, followed by genetic counseling and testing when indicated — before treating a population estimate as yours.
Let's separate two things that get mashed together constantly.
Your baseline risk is the probability you start with. Family history can move this.
The HRT association is the proportional difference observed between users and nonusers. In the 2015 analysis, that relative association was not materially changed by age at use, body size, oral-contraceptive history, hysterectomy, alcohol, tobacco, or family history of breast or ovarian cancer.
That surprises people. It means the data did not show a special larger HRT multiplier solely because a woman reported family history. But if the baseline is higher, the same proportional increase can still translate into a larger absolute difference.
And “family history” in an epidemiology table is not the same as a complete genetics workup.
Which family-history patterns deserve formal risk assessment?
The USPSTF recommends using a brief familial-risk assessment tool for women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer, or an ancestry associated with BRCA1/2 variants. A positive assessment should lead to genetic counseling and, when indicated after counseling, testing.
Patterns that should be brought to a clinician or genetic counselor include:
- Ovarian, fallopian-tube, or primary peritoneal cancer in a close relative
- Multiple relatives on the same side of the family with breast, ovarian, tubal, pancreatic, or aggressive prostate cancer
- Breast cancer at a young age
- Breast and ovarian cancer in the same person or family branch
- Male breast cancer
- A known BRCA1, BRCA2, Lynch syndrome, or other hereditary-cancer variant in the family
- Ashkenazi Jewish ancestry alongside a relevant cancer history; harmful BRCA variants occur in about 2% of people of Ashkenazi Jewish descent, compared with roughly 0.2%–0.3% in the general population
- Young-onset colorectal and endometrial cancers clustering in a family, which can point toward Lynch syndrome
A family history does not automatically mean you carry a pathogenic variant. It means the question deserves a better tool than guesswork.
What if you already know you carry BRCA1, BRCA2, or Lynch syndrome?
Then honestly, this page is not the right decision tool for you.
The National Cancer Institute estimates lifetime ovarian-cancer risk at:
- 39%–58% with a harmful BRCA1 variant
- 13%–29% with a harmful BRCA2 variant
- About 1.1% in the general population
Those ovarian-cancer figures include fallopian-tube and primary peritoneal cancers in the NCI definition.
Lynch syndrome carries a different pattern and different gene-specific risks. Your plan can include decisions about surveillance limitations, risk-reducing surgery, timing of surgery, and the separate question of menopausal hormone therapy after early surgical menopause.
Go to a genetics service or high-risk clinic. A routine online intake is not built to settle this, and any service that treats a known hereditary-cancer syndrome as ordinary history is not the right starting point.
→ See which HRT care path fits your history — the tool asks about safety history and flags when in-person or specialist care should come before a telehealth match.
Should you get a CA-125 test or ultrasound before starting HRT?
No — not routinely, when you have no symptoms and no known high-risk hereditary syndrome. The USPSTF recommends against ovarian-cancer screening with CA-125, transvaginal ultrasound, or both because screening has not reduced ovarian-cancer deaths and false positives can lead to unnecessary surgery in women who do not have cancer.
This is the question women ask constantly, usually phrased as: “Surely it is worth checking, just to be safe?”
The honest answer is that routine screening is not safer.
Why can “just to be safe” cause harm?
Ovarian cancer is uncommon, and available screening tests are not specific enough for average-risk, asymptomatic women. In major trials, 0.2%–3.25% of screened women underwent surgery after a false-positive result, depending on the strategy; up to 15% of those women had a major surgical complication. Screening did not reduce mortality.
CA-125 can rise for benign reasons, including endometriosis, fibroids, inflammation, menstruation, and other conditions. Ultrasound can find cysts and abnormalities that are not cancer.
A positive result can start a chain: repeat testing, more imaging, specialist referrals, anxious waiting, and sometimes surgery to remove an ovary or both ovaries when cancer is not present.
The USPSTF evidence review found no ovarian-cancer mortality reduction from screening in asymptomatic women not known to have a high-risk hereditary syndrome. The harms were moderate to substantial.
What is the difference between screening and evaluating a symptom?
Screening means testing an asymptomatic person in the hope of finding early disease. Evaluation means investigating a symptom, examination finding, or high-risk history. The recommendation against routine screening must never be used to dismiss new persistent symptoms or to block specialist management for someone with a hereditary cancer syndrome.
If you have the symptom pattern in the next section, CA-125 or ultrasound may be appropriate as part of a clinician-directed evaluation. That is not routine screening.
What are the exceptions?
The USPSTF recommendation applies to asymptomatic women who are not known to have a high-risk hereditary cancer syndrome. It does not decide management for women with BRCA1, BRCA2, Lynch syndrome, concerning symptoms, an abnormal examination, or a known adnexal mass.
Starting HRT is not, by itself, a reason to order CA-125 or transvaginal ultrasound in an asymptomatic woman at average inherited risk. If a provider offers screening as reassurance, ask what evidence supports it and what would happen after an abnormal result.
Which symptoms need a proper look instead of another article?
Persistent bloating or increased abdominal size, pelvic or abdominal pain, difficulty eating or feeling full quickly, and urinary urgency or frequency deserve evaluation when they are new or a clear change from your normal. The validated Symptom Index used a threshold of more than 12 times a month with onset within the past year.
This is the section we'd keep if we had to delete every other one.
What pattern did the Ovarian Cancer Symptom Index use?
The original Symptom Index was considered positive when at least one of six symptoms occurred more than 12 times a month and had begun within the previous year. It is not a home diagnostic test. It is a practical description of persistence and change that can help you explain the pattern to a clinician.
The six symptoms were:
- Pelvic pain
- Abdominal pain
- Increased abdominal size
- Abdominal bloating
- Difficulty eating
- Feeling full quickly
A related consensus statement also emphasizes urinary urgency or frequency and a change from your normal.
Separately, any vaginal bleeding after menopause should be evaluated promptly. That is not a specific ovarian-cancer symptom, but it is a red flag on hormone therapy labels and can require evaluation for other gynecologic causes.
Why are we telling you this on an HRT page?
Here's the uncomfortable overlap.
Several ovarian-cancer symptoms can also appear as benign menopausal complaints, gastrointestinal problems, urinary conditions, or adverse reactions listed for specific hormone products. Bloating, abdominal or pelvic discomfort, nausea, and urinary complaints can all have ordinary explanations.
We are not saying HRT hides ovarian cancer. That would be alarmist and unsupported.
What we're saying is subtler and more useful: when a new symptom has an obvious innocent explanation sitting right there, it is easier for everyone — you, your partner, your prescriber — to stop at the innocent explanation.
“It's probably just the HRT” is an easy sentence to say.
So if the pattern is new and persistent, say the other sentence too:
“I know this could be the hormones. I'd still like it looked at.”
What number should stop you from spiraling?
Most women with these symptoms do not have ovarian cancer. In a case-control study of 812 women with ovarian cancer and 1,313 controls, the positive predictive value of the symptom pattern was about 0.6%–1.1%, and below 0.5% for early-stage disease. That study supports evaluation — not panic.
Bloating is far more likely to have another cause than ovarian cancer. The point of the frequency-and-newness rule is not to make you count every sensation. It gives you a threshold so you are neither dismissing a persistent change nor panicking over one bad week.
What should you say at the appointment?
Do not lead only with the diagnosis you fear. Lead with the pattern:
“I've had [symptom] most days for about [X] weeks. It's new for me and different from my normal. I'd like it evaluated rather than assumed to be menopause or my HRT.”
That gives the clinician something concrete.
Do not stop prescribed HRT on your own because you read this section. Get evaluated, and let the medication be part of that conversation.
What does your hysterectomy or ovary surgery change?
A hysterectomy with one or both ovaries left in place does not eliminate ovarian-cancer risk. Removing both ovaries and fallopian tubes greatly reduces ovarian and tubal cancer risk, but primary peritoneal cancer remains possible. And “total hysterectomy” means removal of the uterus and cervix — it does not tell you whether the ovaries were removed.
What is the “total hysterectomy” trap?
In everyday conversation, “total hysterectomy” often gets used to mean “they took everything.” Medically, it means the uterus and cervix were removed. Ovary removal is a separate procedure: oophorectomy. Fallopian-tube removal is salpingectomy.
Plenty of women believe their ovaries are gone when they are not — and some believe they still have them when they do not.
The question is not only “what kind of hysterectomy did I have?” It is: do I still have one or both ovaries, and were the fallopian tubes removed?
Your operative report or pathology report should say. You can request it from the hospital or surgeon's office.
What does each surgical history mean for the HRT question?
Surgery changes both baseline cancer risk and the usual hormone regimen. Women with hysterectomy and ovaries retained often receive estrogen without a progestogen, which is the population represented in the WHI estrogen-alone trial. Women after bilateral ovary removal face a broader surgical-menopause decision in which age and consequences of early estrogen loss matter.
| Your surgery | What remains of ovarian-cancer risk | What it means for this HRT decision |
|---|---|---|
| Hysterectomy, both ovaries retained | Ovarian risk remains because the ovaries remain | Estrogen alone is commonly considered when no uterus is present; this is the population in the WHI CEE-alone trial |
| One ovary removed | Ovarian cancer can still arise in the remaining ovary, and tubal or peritoneal cancer may still occur | Regimen still depends mainly on whether the uterus remains and on the full medical history |
| Both ovaries and fallopian tubes removed | Ovarian and tubal risk is greatly reduced; primary peritoneal cancer remains possible | The decision shifts toward surgical-menopause consequences, age at surgery, symptoms, cancer history, dose, route, and duration |
| Uterus and ovaries intact | Baseline ovarian risk remains | Estrogen normally requires endometrial protection with an appropriate progestogen if systemic therapy is used |
That first row deserves emphasis. If you've had a hysterectomy with ovaries conserved, you have ongoing ovarian-cancer risk and are in the group commonly offered estrogen alone. That makes the 2024 WHI finding especially relevant to the questions you bring to a prescriber — without proving that your exact estradiol product has the same effect.
Does endometriosis change HRT and ovarian cancer risk?
Endometriosis changes the baseline conversation, but one cohort does not justify a universal regimen rule. In a nationwide study of 20,608 postmenopausal women with endometriosis, HRT overall was not associated with more ovarian cancer. The estrogen-only subgroup had a higher risk estimate; combined estrogen-progestogen and tibolone subgroups did not show significant increases.
Endometriosis is independently associated with higher risks of some ovarian-cancer subtypes, especially endometrioid and clear-cell cancers. That means women with endometriosis do not start from exactly the same baseline as women without it.
The 2023 nationwide cohort found:
- Ovarian cancer in 0.3% of HRT users versus 0.5% of nonusers overall
- No significant overall increase associated with HRT use
- An estrogen-only subgroup hazard ratio of 2.898 (95% CI 1.251–6.715)
- No significant increase in the combined estrogen-plus-progestogen or tibolone subgroups
The estrogen-only result deserves attention. It also deserves its limitations: this was observational claims-based research, HRT duration averaged about 1.4 years, and subgroup estimates were built on few ovarian-cancer events.
So the honest conclusion is not “progesterone cancels ovarian risk.” It is:
With an endometriosis history, do not let the usual “no uterus means estrogen alone” shortcut settle the regimen without discussing residual endometriosis, symptoms, surgery, and the limited ovarian-cancer evidence.
That conversation belongs with a clinician who understands both menopause and endometriosis.
Can you take HRT after ovarian cancer?
This is an oncology decision, not an online-provider decision. The small AHT randomized trial found better overall and relapse-free survival among women assigned hormone therapy after epithelial ovarian cancer, and newer observational cohorts have not shown worse survival. But tumor histology matters, evidence remains limited, and hormone-sensitive subtypes require a different approach.
We nearly left this section out because it cannot be resolved properly here. We kept it because women in surgical menopause after ovarian-cancer treatment are still told “no hormones, ever,” and the evidence is not that simple.
The AHT randomized trial assigned 150 women after epithelial ovarian cancer to hormone therapy or no hormone therapy. At a median follow-up of about 19 years:
- 53 of 75 women in the hormone-therapy group had died
- 68 of 75 women in the control group had died
- Overall survival favored hormone therapy: HR 0.63 (95% CI 0.44–0.90)
- Relapse-free survival also favored hormone therapy: HR 0.67
That is a real randomized result. It does not prove hormone therapy itself caused the survival difference beyond doubt. The trial was small, open-label, stopped recruitment early, included mixed regimens, and began under older oncology treatment protocols.
More recent evidence is directionally reassuring rather than definitive. A 2025 Australian cohort found no worse survival associated with post-diagnosis menopausal hormone therapy among women aged 55 or younger with high-grade serous ovarian cancer; the estimate was imprecise because relatively few women used therapy. A 2026 Swedish nationwide cohort likewise reported that postoperative menopausal hormone therapy was not associated with impaired 10-year survival after surgically treated ovarian cancer.
The carve-out matters: epithelial ovarian cancer is not one hormone-sensitivity category. Granulosa-cell tumors and low-grade serous ovarian carcinoma can be hormone responsive and should not be folded into broad reassurance about menopausal hormone therapy. Treatment decisions also differ by stage, receptor biology, remission status, age, and current cancer therapy.
What to do with this:
“I've read the AHT trial and the newer survival cohorts. Given my exact histology, stage, receptor status, treatment, and recurrence risk, does any of that apply to me?”
Take that question to a gynecologic oncologist and a clinician experienced in menopause after cancer.
There is no provider CTA in this section, and there shouldn't be. This decision needs oncology and menopause care working together.
What do major guidelines and authorities actually say?
The current guidance does not say that HRT has no ovarian-cancer risk. The Menopause Society describes a small observational risk, principally serous, while noting no significant increase in the WHI combined-therapy trial. FDA labels retain ovarian warnings. The USPSTF recommends against routine screening in asymptomatic average-risk women. No authority turns these into one personal percentage.
| Source | Current position relevant to this page | Practical meaning |
|---|---|---|
| The Menopause Society, 2022 | Observational evidence shows a small but significant ovarian-cancer risk, principally serous; the WHI estrogen-plus-progestogen trial did not show a significant increase. The statement estimates roughly one additional ovarian-cancer death per 1,700–3,300 users | The risk is small, regimen and route matter, and decisions should be individualized and periodically reviewed |
| FDA product labels, February 2026 | Ovarian cancer remains in warning sections; class-level observational estimates are still used; the 2024 long-term WHI paper is not cited in the six labels audited | Read the exact product label, but do not mistake one pooled number for a product-specific personal risk |
| USPSTF ovarian-cancer screening recommendation | Recommends against routine CA-125, transvaginal ultrasound, or other screening in asymptomatic women without known high-risk hereditary syndromes | Do not order screening merely because HRT is being considered; evaluate symptoms and inherited risk separately |
| National Cancer Institute BRCA fact sheet | BRCA1 and BRCA2 pathogenic variants raise lifetime ovarian-cancer risk far above population risk | Known inherited risk belongs with genetics and high-risk care, not a generic online-HRT pathway |
| American Cancer Society 2026 statistics | Lifetime diagnosis risk about 1 in 91; incidence has declined, likely partly because of more oral-contraceptive use and less menopausal hormone therapy use | Provides population context, not an individual forecast |
One useful pattern: guidance is more careful about ovarian cancer than many consumer articles are. The 2024 WHI result has added a treatment-specific signal that current class labeling does not yet cite. That is worth discussing without pretending it settles every modern prescription.
What can't this page tell you?
We cannot tell you whether HRT would cause ovarian cancer in you. Neither can a label, genetic test, online calculator, or clinician produce a precise personal percentage from the evidence currently available. The studies estimate groups, conflict by regimen and design, and leave major gaps for modern estradiol routes, progestogens, low doses, and local therapy.
Time to be straight with you about the limits here, because everything above is only as useful as its honesty.
The 1-per-1,000 figure comes from observational research. Its authors said the association may be causal; they did not prove causation. About half of the studies with relevant data had not been published. A newer meta-analysis produced smaller pooled estimates. The WHI randomized evidence found a significant signal in one exact estrogen-alone regimen and no significant increase in one exact combined regimen. The French E3N cohort pointed in a different treatment-pattern direction.
Anyone offering you a precise personal percentage is selling certainty that does not exist.
Which is exactly why more reading isn't your next step.
You now know what the studies can tell you. What a webpage cannot do is place your family history, surgical history, symptoms, age, years since menopause, exact product, route, dose, and reason for treatment into one decision.
That needs a person.
If you are the wrong reader for what comes next, where should you go?
We'd rather lose you to the right door than convert you through the wrong one:
- Known BRCA1, BRCA2, Lynch syndrome, or another hereditary ovarian-cancer syndrome → genetics or a high-risk clinic, coordinated with menopause care. Not a routine online intake.
- A personal history of ovarian, fallopian-tube, or primary peritoneal cancer → gynecologic oncology, coordinated with menopause care.
- New persistent symptoms or any bleeding after menopause → an in-person clinical assessment. Return to the HRT decision after the symptom is addressed.
- A strong family pattern that has never been assessed → a brief familial-risk tool, then genetic counseling and testing if indicated.
- A pelvic mass, abnormal imaging, or elevated CA-125 already under investigation → the clinician or specialist managing that workup.
None of those routes runs through an affiliate button, and none of them should.
Where can you take this question if you do not have a clinician?
If the risk question is resolved and the remaining problem is access, look for a clinician who takes a complete cancer and family history, distinguishes estrogen-only from combined therapy, identifies the exact route and product, and can order or coordinate local evaluation when symptoms or history require it. A virtual service can handle the conversation; it cannot perform the pelvic exam.
Here's what separates a useful HRT consult from a form-fill prescription, using our five pillars — clinical legitimacy, care quality, medication fit, price transparency, and access.
What should you verify before paying an online HRT service?
An online service is a reasonable starting point only when your issue can be handled by history, shared decision-making, prescribing, and coordinated local testing. The intake should capture cancer history, family history, uterus and ovary status, current symptoms, and medication route. It should also tell you what happens when online care is not enough.
- Does the intake ask about ovarian, breast, endometrial, colon, and hereditary cancer history? If it does not, it cannot route this question properly.
- Does a licensed clinician review the history in a real visit? A form alone cannot weigh a family pattern or a new symptom.
- Can the clinician order labs or imaging locally and refer you for an in-person examination? Telehealth cannot perform the exam itself.
- Which exact medication is being offered? FDA-approved and compounded products must be labeled separately. Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. The ovarian-risk evidence on this page does not establish a risk estimate for a specific compounded preparation.
- What will the visit cost, what does insurance cover, and are medication, labs, imaging, and follow-ups separate? Do not accept a guessed “starting at” total.
- What happens if you report new bleeding, persistent bloating, pelvic pain, or urinary changes during treatment? The answer should be evaluation or referral, not an automatic dose adjustment.
Which care route fits this specific question?
Midi is entirely virtual: it cannot perform a pelvic examination in the visit. If a hands-on exam is the immediate priority, start with a local gynecology service; Sesame may help you search cash-pay in-person availability, but its terms say availability and price are provider-dependent and not guaranteed. For a history-focused video consult, Midi can order local labs or imaging when needed.
That is the damaging admission, and it matters.
Midi does not give you a physical clinic exam. If that is what you need today, a local gynecologist is the better route. Sesame can be one way to search for cash-pay in-person appointments, but it is a marketplace and cannot guarantee a provider, schedule, or price in your area.
But if your real question is:
“Does my family history change this, and is my estrogen-only prescription the kind of regimen the WHI finding tested?”
—that is primarily a history-and-decision conversation. Midi's official site says initial visits are virtual, clinicians review the full health history, and the service sends patients to local laboratories and imaging centers when testing is needed.
Provider facts verified August 6, 2026
The table below separates provider-stated facts from our editorial fit conclusion. Midi publishes fixed self-pay visit prices and broad state availability. Sesame is cash-pay and publishes service features, lab exceptions, and cancellation terms, but a universal in-person gynecology price is not available because independent providers set availability and pricing.
| Decision fact | Midi Health — provider-stated | Sesame — provider-stated | What it means here |
|---|---|---|---|
| Care model | Virtual clinician visits; initial visit 30 minutes, follow-ups 15 minutes | Virtual menopause subscription plus a marketplace; some in-person services may be located through its care-finder team | Neither virtual pathway replaces an urgent hands-on examination |
| Availability | Available in all 50 states | Availability depends on service, state, and independent provider | Confirm at booking; do not assume a specific clinician or appointment exists |
| Self-pay price | $250 initial visit; $150 continued-care visit | No universal in-person gynecology price verified; listed appointment or subscription price is shown through the booking flow | Midi is the clearer fixed-price video option; Sesame pricing must be checked for the exact service |
| Insurance | In-network with most PPO plans; coverage, deductibles, coinsurance, and copays vary. Not enrolled in Medicaid or Medi-Cal and cannot treat those patients even self-pay. Medicare beneficiaries may use self-pay but cannot submit claims | Does not accept Medicare, Medicaid, or other third-party insurance for services | Coverage status can disqualify the route before clinical fit does |
| Testing | Sends patients to local labs and imaging centers when ordered | Basic labs may be included when ordered in the menopause subscription, with state-specific exceptions; in-person service availability varies | Ask where imaging or an exam happens before paying |
| Medication model | Offers FDA-approved prescriptions and also advertises compounded estradiol and progesterone options in specific circumstances | Provider may prescribe listed hormonal or nonhormonal medications; medication cost is separate and depends on pharmacy and insurance | Ask for the exact product and whether it is FDA-approved or compounded before agreeing |
| Main limitation | No in-visit physical examination | Marketplace availability and price are not guaranteed; no insurance billing | Choose based on whether you need a decision conversation or a hands-on examination |
Our editorial read: for an uncomplicated, history-focused HRT decision in a state Midi serves — which is currently all 50 states — Midi is the cleaner first route because it publishes visit prices, takes many PPO plans, uses a clinician video visit, and coordinates local testing. It is not the route for Medicaid or Medi-Cal patients, and it is not a substitute for an examination when symptoms require one.
For cash-pay readers who need to search for a local hands-on appointment, Sesame can be a useful secondary route. Its official terms state that it does not accept Medicare, Medicaid, or any other third-party insurance, and that in-person availability and pricing are set by providers and are not guaranteed. Its advertised menopause medications are sent to a preferred pharmacy when prescribed; medication cost is not included in the subscription price.
We have intentionally left compounded-only services off this page. This page's original evidence block is built around FDA labels and named published regimens. Routing a cancer-risk reader straight to a compounded-only product with no FDA-approved label would create more uncertainty, not less.
Affiliate disclosure: The HRT Index may earn a commission at no extra cost to you if you use the sponsored Midi or Sesame links below. Commercial relationships do not change the facts or the disqualification rules on this page. See our affiliate disclosure.
→ Check Midi availability and insurance for your state — sponsored link; self-pay is currently $250 for the initial visit and $150 for continued-care visits. Those are visit prices; confirm medication, laboratory, and imaging costs with Midi and your plan.
→ Search Sesame for cash-pay virtual or in-person availability — sponsored link; availability and price depend on the selected provider and service, and Sesame does not bill insurance.
How did we build and verify this page?
We read the primary documents instead of copying a risk number from another article. Every major figure traces to a named study, authority, or dated FDA label. The original asset is the six-label ledger: product, route, warning language, evidence source, revision date, and whether the 2024 WHI analysis appears in the references.
This page follows The HRT Index Verification Standard — our documented process for reviewing providers and medical-commercial claims: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule.
FDA documents read firsthand on August 6, 2026
The original label ledger below is reproducible: each row links to the FDA-hosted prescribing information, identifies the agency Reference ID, and records the revision date. Rechecking those same six documents is the fastest way to catch a new ovarian-cancer paragraph, revised estimate, or added citation during the next update.
| Document | FDA Reference ID | Revision |
|---|---|---|
| Divigel prescribing information | 5744952 | 2/2026 |
| Cenestin prescribing information | 5744928 | 2/2026 |
| Enjuvia prescribing information | 5744927 | 2/2026 |
| Estring prescribing information | 5744942 | 2/2026 |
| Bijuva prescribing information | 5744948 | 2/2026 |
| Prometrium prescribing information | 5744934 | 2/2026 |
| FDA relabeling product list | — | Current August 2026 |
Key medical sources
- Collaborative Group on Epidemiological Studies of Ovarian Cancer, Lancet 2015 — individual-participant meta-analysis of 52 studies
- Chlebowski et al., WHI long-term randomized follow-up, Journal of Clinical Oncology 2024
- 2024 systematic review and meta-analysis of cohort and case-control studies
- Fournier et al., French E3N cohort, 2023
- 2019 ovarian-cancer subtype meta-analysis
- The Menopause Society 2022 Hormone Therapy Position Statement
- USPSTF ovarian-cancer screening recommendation
- NCI BRCA fact sheet
- American Cancer Society 2026 ovarian-cancer statistics
- Ovarian Cancer Symptom Index validation
- Symptom positive-predictive-value study
- Endometriosis, HRT, and ovarian-cancer cohort
- AHT randomized trial after epithelial ovarian cancer
- 2025 post-diagnosis MHT and ovarian-cancer survival cohort
- 2026 Swedish postoperative MHT and 10-year survival cohort
Provider facts rechecked August 6, 2026
- Midi pricing and insurance
- Midi availability and care model
- How Midi orders local labs and imaging
- Sesame menopause service details
- Sesame terms, insurance, availability, and cancellation policy
Why are there no testimonials on this page?
You will not find a customer story positioned as proof that HRT is safe or unsafe for ovarian cancer. A woman taking hormone therapy and not developing cancer is not evidence about causation, and putting that story beside a risk statistic would imply a claim it cannot support.
The authority here comes from trial results, observational data, FDA labels, current provider terms, and the parts that do not line up cleanly.
Author: The HRT Index Editorial Team. This is editorial research, not medically reviewed by a clinician, and not medical advice. Last verified: August 2026.
Frequently asked questions
Does HRT cause ovarian cancer?
Studies consistently find an association, and the largest individual-participant meta-analysis said the increase may be largely or wholly causal. Observational studies cannot prove cause. The 2024 randomized WHI follow-up found a significant long-term increase with oral conjugated equine estrogen alone, while the separate CEE-plus-MPA trial did not show a significant increase.
How much does HRT increase ovarian cancer risk in absolute numbers?
The most cited estimate is about one additional ovarian cancer per 1,000 women who use systemic HRT for five years from around age 50, and one additional ovarian-cancer death per 1,700 users — if the association is causal. That is a group estimate, not a personal forecast.
Is estrogen-only HRT worse than combined HRT for ovarian cancer?
The 2024 WHI follow-up found higher ovarian-cancer incidence and mortality with one exact estrogen-only regimen: oral conjugated equine estrogen 0.625 mg. The separate trial of oral CEE plus medroxyprogesterone acetate did not show a significant increase. Those two trials do not prove a universal difference between every estrogen-only and combined product.
Which HRT is safest if you are worried about ovarian cancer?
No product has been shown to be “ovarian-safe.” The strongest randomized signal concerns oral conjugated equine estrogen alone. There is not enough ovarian-cancer evidence to declare a patch, gel, low dose, specific progestogen, or compounded formulation safest. Choose the exact regimen through a full benefit-risk discussion rather than one cancer outcome alone.
Does a patch lower ovarian cancer risk compared with a pill?
No reliable study has shown that a patch lowers ovarian-cancer risk. Transdermal estrogen may be selected for other clinical reasons, but route-specific ovarian-cancer data are insufficient and the oral-versus-transdermal subgroup evidence has not shown a significant difference.
Does ovarian cancer risk go away after stopping HRT?
The association declines after stopping and is strongest during current or recent use. The exact timeline is unsettled: the 2015 analysis found some residual elevation around ten years after longer use, while The Menopause Society summarizes the excess risk as dissipating within about five years.
Can you take HRT if your mother had ovarian cancer?
Family history raises concern about baseline and inherited risk, but it is not automatically a contraindication. Use a brief familial-risk assessment and pursue genetic counseling or testing when indicated. The 2015 analysis did not find that family history materially changed the proportional HRT association.
Can you take HRT with a BRCA1 or BRCA2 variant?
That decision belongs with a genetics or high-risk clinic coordinated with menopause care. NCI estimates lifetime ovarian-cancer risk at 39%–58% with BRCA1 and 13%–29% with BRCA2, compared with about 1.1% in the general population. General-population HRT estimates cannot settle that plan.
Does vaginal estrogen increase ovarian cancer risk?
No ovarian-cancer trial has established a product-specific risk for low-dose vaginal estrogen. Estring's FDA label carries the systemic class warning while stating that systemic exposure is generally lower and the relevance of systemic risks is unknown. Systemic estimates should not be applied automatically, but zero risk has not been proved.
Can you take HRT after ovarian cancer?
Sometimes, but only through oncology-led decision-making. The AHT randomized trial and newer cohorts did not show worse survival and in some analyses outcomes favored hormone therapy. Evidence is limited, and hormone-sensitive histologies such as granulosa-cell tumors and low-grade serous ovarian carcinoma require different caution.
Did the FDA remove the ovarian cancer warning from HRT in 2026?
No. The February 2026 changes removed specified cardiovascular-disease, breast-cancer, and probable-dementia statements from boxed warnings on six products. Ovarian cancer was not in the boxed warning. It remains in Warnings or Warnings and Precautions in all six labels audited.
Do you need a CA-125 test before starting HRT?
Not routinely when you have no symptoms and no known high-risk hereditary syndrome. The USPSTF recommends against ovarian-cancer screening with CA-125, transvaginal ultrasound, or both in asymptomatic average-risk women because screening does not reduce deaths and can cause false positives and unnecessary surgery.
What are the early symptoms of ovarian cancer?
Persistent bloating or increased abdominal size, pelvic or abdominal pain, difficulty eating or feeling full quickly, and urinary urgency or frequency can warrant evaluation when new or different from your normal. The validated Symptom Index used more than 12 occurrences a month with onset within the prior year. Most women with these symptoms do not have ovarian cancer.
Is there an effective ovarian cancer screening test for average-risk women?
No screening strategy has been shown to reduce ovarian-cancer mortality in asymptomatic women at average inherited risk. CA-125 and transvaginal ultrasound are used to evaluate symptoms or abnormalities, but that is different from routine screening.
Still not sure which HRT program is right for you?
Use our free, private matching tool.
Find My HRT Path asks about your symptoms, surgical history, safety history, state, treatment preference, and payment route — then shows the best-fit online care path and two backup routes, while flagging when online care is not the right first step. It takes about 90 seconds and does not require an email.
Find My HRT Path is educational routing, not diagnosis or medical advice. The live tool states that nothing is sold or stored, no account is required, and health answers never leave the page. A licensed clinician makes all treatment decisions. See our Consumer Health Data Privacy Policy.